Cargando…

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum

INTRODUCTION: Amyloid beta (Aβ), tau, and neurodegeneration jointly with the Alzheimer's disease (AD) risk factors affect the severity of clinical symptoms and disease progression. METHODS: Within 248 Aβ‐positive elderly with and without cognitive impairment and dementia, partial least squares...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tosun, Duygu, Demir, Zeynep, Veitch, Dallas P., Weintraub, Daniel, Aisen, Paul, Jack, Clifford R., Jagust, William J., Petersen, Ronald C., Saykin, Andrew J., Shaw, Leslie M., Trojanowski, John Q., Weiner, Michael W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Featured Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014819/ https://www.ncbi.nlm.nih.gov/pubmed/34647694 http://dx.doi.org/10.1002/alz.12480

Ejemplares similares

Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report
por: Weiner, Michael W., et al.
Publicado: (2017)

Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers
por: Tosun, Duygu, et al.
Publicado: (2021)

Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease
por: Veitch, Dallas P., et al.
Publicado: (2021)

Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer’s disease in veterans, using the Alzheimer’s Disease Neuroimaging Initiative
por: Weiner, Michael W., et al.
Publicado: (2014)

Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4
por: Weiner, Michael W., et al.
Publicado: (2022)

Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer’s disease
por: Nho, Kwangsik, et al.
Publicado: (2016)

Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease
por: Nho, Kwangsik, et al.
Publicado: (2017)

Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition
por: Vemuri, Prashanthi, et al.
Publicado: (2011)

Preclinical Alzheimer's disease and longitudinal driving decline
por: Roe, Catherine M., et al.
Publicado: (2016)

On the path to 2025: understanding the Alzheimer’s disease continuum
por: Aisen, Paul S., et al.
Publicado: (2017)

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2014)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
por: Van Hulle, Carol, et al.
Publicado: (2020)

Early Indications of Future Cognitive Decline: Stable versus Declining Controls
por: Rizk-Jackson, Angela, et al.
Publicado: (2013)

Alzheimer risk genes modulate the relationship between plasma apoE and cortical PiB binding
por: Lazaris, Andreas, et al.
Publicado: (2015)

The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease
por: Li, Dan, et al.
Publicado: (2019)

Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study
por: Yagi, Takuya, et al.
Publicado: (2019)

Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease
por: Insel, Philip S, et al.
Publicado: (2015)

Extracellular vesicle biomarkers of Alzheimer's disease associated with sub‐clinical cognitive decline in late middle age
por: Eren, Erden, et al.
Publicado: (2020)

The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI)
por: Risacher, Shannon L., et al.
Publicado: (2013)

Network‐wise concordance of multimodal neuroimaging features across the Alzheimer's disease continuum
por: Stocks, Jane, et al.
Publicado: (2022)

Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease
por: Libiger, Ondrej, et al.
Publicado: (2021)

Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease
por: Villeneuve, Sarah-Christine, et al.
Publicado: (2019)

Telomere length associations with cognition depend on Alzheimer's disease biomarkers
por: Mahoney, Emily R., et al.
Publicado: (2019)

Cerebral amyloid‐β load is associated with neurodegeneration and gliosis: Mediation by p‐tau and interactions with risk factors early in the Alzheimer's continuum
por: Salvadó, Gemma, et al.
Publicado: (2021)

Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum
por: Toledo, Jon B., et al.
Publicado: (2022)

Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease
por: Lim, Nicholas S., et al.
Publicado: (2016)

PTSD and the COVID-19 Continuum
por: Prestia, Angela S.
Publicado: (2022)

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease
por: Jack, Clifford R., et al.
Publicado: (2010)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease
por: Apostolova, Liana G., et al.
Publicado: (2014)

Effects of Baseline CSF α-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer’s Disease
por: Mattsson, Niklas, et al.
Publicado: (2013)

Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology
por: Laforce, Robert, et al.
Publicado: (2014)

Normalization of CSF pTau measurement by Aβ(40) improves its performance as a biomarker of Alzheimer’s disease
por: Guo, Tengfei, et al.
Publicado: (2020)

A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease
por: Chen, Yun-Fei, et al.
Publicado: (2018)

The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives
por: Weber, Christopher J., et al.
Publicado: (2021)

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease
por: Baldaranov, Dobri, et al.
Publicado: (2023)

Subjective cognitive decline: opposite links to neurodegeneration across the Alzheimer’s continuum
por: Kuhn, Elizabeth, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i1ufej0cb9vvmd03g4noljkqnh